Drug intelligence / Profile preview

Bio-Oss Collagen

Development stage: Unknown
Lead developer: Geistlich Pharma
Administration: Surgical Implantation

Overview

Geistlich Bio-Oss Collagen is a sterile, biocompatible bone substitute material composed of 90% bovine-derived xenograft bone mineral granules and 10% porcine collagen fibers. Developed by Geistlich Pharma AG, it is used in oral and maxillofacial surgery as an osteoconductive scaffold to support and promote new bone formation. The bovine bone mineral component provides long-term volume stability due to its low resorption rate, while the added collagen improves the handling properties, allowing the material to be easily molded and adapted to the defect site. It is primarily indicated for guided bone regeneration (GBR), ridge preservation following tooth extraction, and bone augmentation around dental implants.

Brand names: Bio-Oss CollagenGeistlich Bio-Oss Collagen
Other names: Geistlich Bio-Oss® Collagen

Beyond the preview

Go deeper on Bio-Oss Collagen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio-Oss Collagen.

Explore the full profile